They would buy this out while it's still cheap...that way they can maintain Total Control of the Hep C market and they could take their sweet time with this. $2.5 Billion is a drop in the bucket for Gilead, because if this drug is approved it will end up costing them about $5 to $10 Billion in the long run.
There is No approvals for CYTR, they are misinformed. No drugs have been applied for the NDA application yet, so as far as "drug approvals" nope....but this stock is still heading MUCH Higher.
Chart looks great...but remember we have multiple patterns within the mainframe also, so there will be some profit taking in the low 3.40's but after that it should come back reloaded and ready for a nice steady run...bottom line, I agree with the analysis. It will happen.
Accomplishments during this two year period: they filed an IND, completed two Phase 1 studies and initiated three Phase 2 studies.
Tell any company that has accomplished this much in two years?
Catalysts: RXII is going to communicate the First readouts from the first P2a study mid-year.
I have a feeling they will be Stellar and have a feeling they have been sitting on these results for the purpose of "Timing" which demonstrates to me that this company absolutely knows what they are doing.
Get Ready...Q3 and Q4 are usually very Exciting times in the biotech arena and NOW is the time to get in.
There are no delivery vehicles needed for this drug.
This will limit toxicity by over 90% and make this a much safer bet.
People don't seem to see the potential of this one drug for scarring. It is a huge business that is has UNMET needs...the FDA should be slightly more lenient on treatments for unmet needs.
Plus: The Retinoblastoma arena is huge also and it goes direct to the source without a delivery vehicle...limits systemic toxicity. This is a HUGE relief for investors.
I have been investing for over 16 years in the biotech arena and have learned that Toxicity is the number one concern. Safety first. I have seen a lot of drugs that would of been blockbusters but had to be dropped due to toxicity and adverse effects in the early stages.
This upcoming news should get this stock on the radar...flying a bit higher so it can be well recognized for the potential it really has.
it's not even funny. A market cap less than $50 Million for this technology that could help Millions and generate Billions a year?
But, I guess it's all a gamble until you know for sure if something works, but read the fine print and connect the dots....maybe you guys will see something similar.
This seriously could be $20 bucks and analysts wouldn't question the value-- why, because of the demand for the product. There is NO product out there and this will be in SUPER High Demand -- who wants an ugly scar?
The CYTR board isn't enough for you?
You obviously have something against GALE, RXII and CYTR...either you are a paid worthless basher or someone(s) did you wrong and you are carrying that grudge with you.
You can gripe and moan all you want...but you are not gong to change anything except your own perception.
For the remainder of the year:
1. The Phase 2b trial in 2nd-line small cell lung cancer (SCLC) will begin. This is an international, multi-center trial enrolling 132 patients with half getting aldoxorubicin and half receiving topotecan.
2. We will report the overall survival (OS) data from the STS Phase 2b trial. This is a secondary endpoint and the trial was not powered to show a statistically significant improvement. However, a trend would be very encouraging. OS requires deaths to occur before we can analyze the data. Thus, there is no way to expedite this. Taking longer could be positive if those living longer had received aldoxorubicin.
3. Start the two Phase 1 combination trials -- Not sure if this will be in 2014 or early 2015?
4. Present data at medical meetings including the European Society for Medical Oncology (ESMO) at the end of September and the Connective Tissue Oncology Society (CTOS) in mid-October. So TWO Presentations before the EOY.
Institutional ownership is now at 43% compared to 11% last fall. Institutions have been accumulating and this will be heading NORTH.
Answers to this question:
This was a Pilot study to gather some general information and not to measure any statistical significance. It was with Dying patients...patients that had failed two or three therapies and some in HOSPICE. There is NO Drug that can help people when they are this sick and have days to a few weeks to live. The investigator advised CYTR to try this at EARLIER stages. Which is exactly what their plan is.
The good thing is that they can jump to a phase II with Aldox.
My speculation that they are thinking about Aldoxorubicin with Gemcitabine was correct and they are in the process of figuring out the right combination doses. In my opinion this is Exactly what they should do and that is what the very intelligent investigator advised.
CYTR has received Orphan Drug Status with Aldoxorubicin treating Pancreatic Cancer. I wouldn't be surprised to see this expedited. Of course these things do take time which is associated with a lot of Red Tape.
Catalysts continued below for the remainder of the year.
I don't want to jump the gun here, but I have a feeling that there will be a trial announced in 2015 that CytRx is going to combine Aldoxorubicin with Gemcitabine for Advanced Pancreatic Cancers. If they maintained a relationship with Dr. Daniel Von Hoff of TGEN then they are in good shape.
The study mentioned above was just a pilot study...a study to gain information on potential future studies...this is purely an educated guess, but I wouldn't be surprised.
I know that animal studies were good. On clinical trials it says "completed" but I am not sure if they every communicated results to investors. On their progress pipeline page on their website it does not say Anything about Advanced Pancreatic Cancer....so I am guessing it was a failure, but I don't know.
I sent out emails to the two contacts on their contact page.
Chief investigator was a good one: Dr. Daniel Von Hoff of TGEN, who dedicates his life to Panreatic Cancer and is international recognized.
I am attempting to contact him at TGEN directly also to get to the bottom of this.
Clinical Trial: ON 2-25-2013 it was active and non recruiting. Then in June it said "Completed" on clinical trials. Once again...if this was successfully completed this would definitely be Highlighted with a number of press releases, because when they have good news they "Milk" it out.
Does anyone know if John Columbo still works their or answers questions. I have spoken with David Haen previously, but not about this.
If anyone knows more email addresses please post and I will do the rest. We deserve to know the answer to this question as it has been in the back of my mind for a year now...maybe it has been answered in the meantime but I haven't viewed it.
Also: others should ask this as I did to see if we receive similar responses: Ask if there are ANY Future plans for Aldoxorubicin for any form of Pancreatic Cancer?
I strongly encourage other investors to contact Cytr to find out what happened with this clinical trial and again anyone with contact info please site as I want to get as many views as I can.
I'm not selling because I think that it is a flat out bargain at these prices and I wouldn't sell this for anything under $15.00 and that's not a joke. BUT, this has to go up to around $8 before anyone of the big boys will make an offer...I know this sounds stupid, but I have observed these big boy morons buy High all the time...they will want one more confirmatory trial to peek interest.
This could be $30 by next year if Kriegsman doesn't get excessively greedy with dilution.
The GB trial could hinder this, but if it hits this is a sure $30 bucks by this time next year.
tried posting the link and I see it is deleted.
I found a similar article on Readcubedotcom
Not sure where Nick found his article, but I'm sure Nick and I are on the same page in general.